Cassimerson's profile and listing information

Casimersen (Casimersen) is an innovative drug for Duchenne muscular dystrophy (DMD), which brings new treatment hope to patients with specific DMD gene mutations. These patients have genetic mutations that allow treatment by skipping exon 45, a mechanism Kasimerson designed to target.

In a double-blind, placebo-controlled study, 43 male patients with DMD aged 7 to 20 years were evaluated. They were randomized in a 2:1 ratio to receive intravenous Kasimerson or placebo. The trial, being conducted at seven sites in five countries, assessed the drug's efficacy by measuring dystrophin levels in muscle biopsies before treatment and at week 48.

Kasimerson dosage is carefully designed to ensure it is effective in achieving therapeutic goals. Although the specific dosing regimen may vary depending on the patient's condition, generally it is administered via intravenous injection once a week, with the dose adjusted based on the patient's weight.

The side effects of Casimerson mainly include upper respiratory tract infection, cough, fever, headache, joint pain and oropharyngeal pain. The incidence of these adverse reactions is relatively high in clinical trials. In addition, because Casimerson is a drug administered by intravenous infusion, infusion-related side effects, such as phlebitis, may occur during use. At the same time, long-term use of Casimerson also requires attention to potential risks such as renal toxicity. Patients should pay close attention to their own conditions during use and seek medical advice in time if they feel uncomfortable.

In February 2021, Kasimerson was approved for medical use in the United States, becoming the first FDA approved A targeted therapy for patients with mutations in the DMD gene, specifically those that can be treated by skipping exon 45. This approval marks an important development in the treatment of DMD.

However, Kasimerson has not yet been launched in my country, so it has not been included in my country's medical insurance system, and the price is still unclear. For DMD patients in my country, they look forward to Kasimerson being launched in the country as soon as possible to provide them with more treatment options.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213026s005lbl.pdf